Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae

Roberta Prinapori, Julie Guinaud, Antoine Khalil, Herve Lecuyer, Dominique Gendrel, Olivier Lortholary, Xavier Nassif, Claudio Viscoli, Jean Ralph Zahar

Research output: Contribution to journalArticlepeer-review


We evaluated 74 children with previous fecal extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae colonization who were hospitalized and receiving a course of antibiotic therapy for suspected infection. Sixty-four patients (86.5%) received a carbapenem agent. Only 3 patients were infected with an ESBL-producing Enterobacteriaceae. Sixty-one (95%) initial antibiotic courses were considered excessive and required deescalation; however, deescalation was accomplished in only 38 patients (62%). This suggests the need for an ESBL control program to decrease carbapenem use and thereby limit carbapenem resistance in gram-negative bacilli.

Original languageEnglish
Pages (from-to)259-260
Number of pages2
JournalAJIC: American Journal of Infection Control
Issue number3
Publication statusPublished - Mar 2013


  • Bloodstream infection
  • Carbapenems
  • Deescalation

ASJC Scopus subject areas

  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • Epidemiology
  • Health Policy


Dive into the research topics of 'Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae'. Together they form a unique fingerprint.

Cite this